Patent · US Active

Lung cancer-targeted peptides and applications thereof

US8415453B2 · kind B2 · utility

0Cited by

11References

13Claims

0Family size

Assignees

ACADEMIA SINICA · TW
National Taiwan University · TW

Inventors

Han-Chung Wu · Taipei, TW
Chin-Tarng Lin · Taipei, TW
De-Kuan Chang · Taipei, TW

Key dates

Filing date	Apr 13, 2007
Grant date	Apr 9, 2013
Priority date	—
Expiry date	Feb 9, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K7/08
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides nucleic acids, peptides, and antibodies for use in applications including diagnosis and therapy. The peptides target lung cancer and were identified by phage display. Targeting phage PC5-2 and synthetic peptide SP5-2 were both able to recognize human pulmonary tumor specimens from lung cancer patients. In SCID mice bearing NSCLC xenografts, the targeting phage was able to target tumor masses specifically. When the peptide was coupled to liposomes containing the anti-cancer drugs vinorelbine or doxorubicin, the efficacy of these drugs against human lung cancer xenografts was improved, the survival rate increased, and the drug toxicity was reduced.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.